Namwiwat Medical Corp PCL
Namwiwat Medical Corp PCL operates in the medical equipment, supplies, and distribution sector, generating revenue primarily through the sale and distribution of medical devices and related healthcare products.
Business. Namwiwat Medical Corp PCL (NAM.BK) is a healthcare services and equipment company engaged in the medical equipment, supplies, and distribution industry. The firm operates primarily through a product-sale revenue model, focusing on the provision of medical devices and related supplies. Headquartered in Thailand, the company is listed on the Stock Exchange of Thailand (SET). Specific details regarding operating segments and geographic revenue mix are not disclosed.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Namwiwat Medical Corp PCL (NAM.BK) is a healthcare services and equipment company engaged in the medical equipment, supplies, and distribution industry. The firm operates primarily through a product-sale revenue model, focusing on the provision of medical devices and related supplies. Headquartered in Thailand, the company is listed on the Stock Exchange of Thailand (SET). Specific details regarding operating segments and geographic revenue mix are not disclosed.
Namwiwat Medical Corp PCL maintains a strong liquidity position with a current ratio of 8.91, indicating a high ability to meet short-term obligations. However, the company reported negative operating cash flow of -48,123,590 THB and free cash flow of -12,124,070 THB, suggesting cash outflows from operations. The capital expenditure of -33,648,790 THB reflects ongoing investment in long-term assets.
Profitability metrics show a return on equity (ROE) of 0.67% and a return on assets (ROA) of 0.58%, both below the typical thresholds for high-performing healthcare firms. The company's operating income of 21,332,120 THB and net income of 13,269,070 THB indicate modest profitability relative to its asset base.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory shifts.
Outlook for the current fiscal year shows a projected revenue growth of 0.00%, with no significant changes expected in the next fiscal year. The company's historical revenue of 200,446,110 THB reflects a stable but non-expanding business model.
Risk factors include a medium liquidity risk due to negative net cash after subtracting total debt. The dilution risk is assessed as low, with no near-term pressure from share issuance or convertible instruments. The company's debt-to-equity ratio of 0.09 suggests a conservative capital structure.
Recent filings and transcripts do not disclose any material events or strategic shifts. The company's financial statements remain consistent with prior periods, with no significant changes in operations or capital structure.
- Namwiwat Medical Corp PCL maintains a strong current ratio but faces negative operating and free cash flows.
- ROE and ROA are below typical thresholds for the healthcare equipment industry.
- Revenue is concentrated in a single business segment with no geographic diversification.
- The company's capital structure is conservative, with a low debt-to-equity ratio.
- No near-term dilution risk is identified, and liquidity remains a medium concern.
Bull / Bear case
Generated · model-assistedRevenue surged 67.8% year-over-year to THB 1.87 billion, demonstrating strong top-line growth momentum.
The debt-to-equity ratio of 0.09 is below the 0.20 cohort median, suggesting a conservative capital structure.
Revenue grew at a 17.2% CAGR over four years, showing consistent long-term expansion despite recent volatility.
Return on equity of 0.67% is below the 1.42% cohort median, indicating poor capital efficiency.
Cash conversion ratio of -3.63 places the company in the bottom quartile of its peer group.
Long-term debt increased to THB 495.3 million, reflecting rising leverage amidst declining profitability.
In focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Namwiwat Medical Corp PCL Market data — financials · 2026-05-28